ME Nassif, SL Windsor, BA Borlaug, DW Kitzman… - Nature medicine, 2021 - nature.com
Patients with heart failure and preserved ejection fraction (HFpEF) have a high burden of symptoms and functional limitations, and have a poor quality of life. By targeting …
Background: Many patients with heart failure and reduced ejection fraction (HFrEF) have chronic kidney disease that complicates pharmacological management and is associated …
Whether the sodium–glucose cotransporter 2 inhibitor dapagliflozin reduces the risk of a range of morbidity and mortality outcomes in patients with heart failure regardless of ejection …
ME Nassif, SL Windsor, K Gosch… - Circulation: Heart …, 2023 - Am Heart Assoc
BACKGROUND: Patients with heart failure (HF) have a high burden of symptoms and physical limitations, regardless of ejection fraction (EF). Whether the benefits of SGLT2 …
Background: Outcome trials in patients with type 2 diabetes mellitus have demonstrated reduced hospitalizations for heart failure (HF) with sodium-glucose co-transporter-2 …
Importance Women may respond differently to certain treatments for heart failure (HF) with reduced ejection fraction (HFrEF) than men. Objective To investigate the efficacy and safety …
Background: Goals of management in patients with heart failure and reduced ejection fraction include reducing death and hospitalizations, and improving health status …
DM Williams, M Evans - Diabetes Therapy, 2020 - Springer
Drug therapies for people with heart failure and preserved ejection fraction (HFpEF) are often limited to diuretics to improve symptoms as no therapies demonstrate a mortality …
P Dewan, SD Solomon, PS Jhund… - European journal of …, 2020 - Wiley Online Library
Aims The aim of this study was to examine whether left ventricular ejection fraction (LVEF) modified efficacy and safety of dapagliflozin 10 mg compared with placebo in the 4744 …